|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, May 27, 2016 ) Pulmonary hypertension is a rare disorder that affects the pulmonary arteries carrying deoxygenated blood to the lungs from the heart. The narrowing or blockage of pulmonary arteries will lead to pulmonary hypertension. Symptoms of the disease do not occur until the disease becomes severe. Certain causes of pulmonary hypertension include emphysema, connective tissue disorders, blood clots in lungs, and sleep apnea. Pulmonary hypertension may sometimes lead to several chronic illnesses, such as kidney failure (renal failure), heart failure, aneurysm, heart attack, or, stroke. Endothelin receptor antagonists, prostacyclin analogs, phosphodiesterase inhibitors, and sGC stimulators are popular drug therapeutic classes available for the treatment of pulmonary hypertension.
Publisher's analysts forecast the global pulmonary hypertension market to grow at a CAGR of 2.92% over the period 2014-2019.
View Report: http://www.reportsweb.com/pulmonary-hypertension-global-market-research-2015-2019 .
The report includes the present scenario and the growth prospects of the global pulmonary hypertension market for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of pulmonary hypertension.
Publisher's report, Global Pulmonary Hypertension Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and pipeline landscape. The report includes a discussion of the key vendors operating in this market.
Key vendors
- Actelion
- Bayer
- GlaxoSmithKline
- United Therapeutics
Inquire Before Buying at http://www.reportsweb.com/inquiry&RW0001232390/buying .
Other prominent vendors
- Aires Pharmaceuticals
- Arena Pharmaceuticals
- Bial
- DEKA
- Dong-A ST
- Gilead
- Merck
- Northern Therapeutics
- Novartis
- Pfizer
- PhaseBio
Key market driver
- Growing incidence of pulmonary hypertension
- For a full, detailed list, view our report
Key market challenge
- Patent expiry
- For a full, detailed list, view our report
Key market trend
- Increased focus on combination therapies
- For a full, detailed list, view our report
Buy Now at http://www.reportsweb.com/buy&RW0001232390/buy/2500 .
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
